ADMA Biologics Inc (ADMA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $10.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Earnings in 5 days (event risk).
ADMA Biologics manufactures plasma-derived IVIG products—ASCENIV (for PI/thalassemia), BIVIGAM (for PI), and Nabi-HB (for Hepatitis B)—at its FDA-licensed Boca Raton, Florida facility with 600,000-liter peak annual capacity. Revenue comes from product sales with net income of... Read more
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $10.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 51. Score 6.1/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerfew customers10-K Item 1A: 'Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect'
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02MEDIUMCFO Brad Tade retiring effective February 25, 2026 after FY2025 10-K filing, succeeded by Terry Kohler (current Executive Financial Advisor). Tade moving to consulting role per separation and consulting agreements.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.1/10 is below the 5.0 floor at $10.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 51. Prior stop was $9.71. Score 6.1/10, moderate confidence.
Take-profit target: $17.57 (+68.2% upside). Prior stop was $9.71. Stop-loss: $9.71.
Leverage penalty (D/E 1.1): -0.5; Earnings in 5 days (event risk); Earnings estimates trending DOWN.
ADMA Biologics Inc trades at a P/E of 17.1 (forward 8.1). TrendMatrix value score: 8.6/10. Verdict: Sell.
9 analysts cover ADMA with a consensus score of 4.0/5. Average price target: $21.
What does ADMA Biologics Inc do?ADMA Biologics manufactures plasma-derived IVIG products—ASCENIV (for PI/thalassemia), BIVIGAM (for PI), and Nabi-HB...
ADMA Biologics manufactures plasma-derived IVIG products—ASCENIV (for PI/thalassemia), BIVIGAM (for PI), and Nabi-HB (for Hepatitis B)—at its FDA-licensed Boca Raton, Florida facility with 600,000-liter peak annual capacity. Revenue comes from product sales with net income of $146.9M in 2025. A few customers historically account for a significant portion of total revenue.